Novartis’ Good News on Gilenya Raises Hopes in ALS

New results from an analysis of Phase III clinical trial data collected from more than 3,600 people showed that Novartis’ new multiple sclerosis (MS) drug, Gilenya (also known as fingolimod) “significantly and consistently reduced the rate of brain volume loss” in people with relapsing and remitting MS. These findings should be encouraging for people with ALS given that this past February, ALS TDI gained FDA approval for a Phase IIa clinical trial to test the safety and tolerability of Gilenya in ALS patients.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail